Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1999-12-22
2000-08-08
Reamer, James H.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 3119
Patent
active
061002976
ABSTRACT:
The intravenous use of magnesium gluconate to substantially block free radical surge in the treatment of ischemia/reperfusion (I/R) injury due to oxidative stress.
REFERENCES:
patent: 5871769 (1999-02-01), Fleming et al.
patent: 5922765 (1999-07-01), Fleming et al.
patent: 5939394 (1999-08-01), Fleming et al.
Biochemical and Biophysical Research Communications; pp. 1102-1106, vol. 170, No. 3, 1990, Freedman, et al "Magnesium Deficiency-Induced Cardiomyopathy: Protection By Vitamin E".
Molecular and Cellular Biochemistry 110: 169-173, 1992; Weglicki, et al; "Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin".
Antioxidant Characterization and Assay; pp. 620-631; Mak, et al; "Antioxidant Activity of Calcium Channel Blocking Drugs"; Methods in Enzymology, vol. 234 (1994).
Biochemical Pharmacology; vol. 40, No. 9, pp. 2169-2175; 1990; Mak, et al; "Protective Effects of Sulfhydryl-Containing Angiotensin Converting Enzyme Inhibitors Against Free Radical Injury in Endothelial Cells".
Biochemical Pharmacology, vol. 50, No. 9, pp. 1531-1534, 1995; "Protective Effects of Calcium Channel Blockers Against Free Radical-Impaired Endothelial Cell Proliferation"; Mak, et al.
Molecular and Cellular Biochemistry, 000:000-000, 1994, Weglicki, et al; "Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition"; pp. 1-7.
Antioxidant Effects of Calcium Channel Blockers Against Free Radical Injury in Endothelial Cells, Correlation of Protection with Preservation of Glutathione Levels, Mak, et al; Circulation Research 70(6), Jun., 1991, pp. 1099-1103.
The FASEB Journal, Abstracts 1-3805; Tutorials T1-T13; Experimental Biology 97; Mak, et al--#396; Apr., 1997.
Reamer James H.
The George Washington University
LandOfFree
Intravenous magnesium gluconate for treatment of conditions caus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Intravenous magnesium gluconate for treatment of conditions caus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intravenous magnesium gluconate for treatment of conditions caus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1150640